Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8752131 | 0.97 | LMNA (0.42) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL371082 | 0.87 | LMNA (0.46) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL9076702 | 0.85 | LMNA (0.44) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL8995619 | 0.85 | LMNA (0.44) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL8760937 | 0.84 | LMNA (0.39) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL332859 | 0.84 | LMNA (0.54) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL8726308 | 0.82 | LMNA (0.41) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL8760935 | 0.81 | TSHR (0.37) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL6358283 | 0.81 | LMNA (0.40) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E | |
| SCHEMBL8814469 | 0.81 | LMNA (0.50) | LMNASMN1; SMN2ALDH1A1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2275094-A2 | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions | Elan Pharma International Limited (IE) | 2011-01-19 | — | — | EP | claimed |
| US-20090081297-A1 | Use of surface tension reducing agents in aerosol formulations | MAP PHARMACEUTICALS, INC. | 2009-03-26 | — | — | US | claimed |
| US-20210251900-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | BAXTER HEALTHCARE SA (CH) | 2021-08-19 | — | — | US | disclosed |
| US-11052043-B2 | Sustained-release injectable formulation | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2021-07-06 | — | — | US | disclosed |
| US-10952965-B2 | Compositions and methods for drug delivery | BAXTER INTERNATIONAL INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10722463-B2 | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier | ZULI HOLDINGS LTD. (IL) | 2020-07-28 | — | — | US | disclosed |
| US-20180193265-A1 | COMPOSITIONS AND METHODS USING SAME FOR DELIVERING AGENTS INTO A TARGET ORGAN PROTECTED BY A BLOOD BARRIER | ZULI HOLDINGS LTD. (IL) | 2018-07-12 | — | — | US | disclosed |
| US-9943481-B2 | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier | BIOREST LTD. (IL) | 2018-04-17 | — | — | US | disclosed |
| EP-2317982-B1 | METHODS OF PROCESSING COMPOSITIONS CONTAINING MICROPARTICLES | BAXTER INT (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9364443-B2 | Compositions and methods for drug delivery | BAXTER INTERNATIONAL, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2334393-B1 | METHODS OF PROCESSING MULTI-PHASIC DISPERSIONS | BAXTER INT (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-0804162-A1 | BUTYLENE OXIDE-ETHYLENE OXIDE BLOCK COPOLYMER SURFACTANTS AS STABILIZER COATINGS FOR NANOCRYSTAL FORMULATION | NanoSystems L.L.C. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1997011686-A1 | REDUCTION OF INTRAVENOUSLY ADMINISTERED NANOPARTICULATE-FORMULATION-INDUCED ADVERSE PHYSIOLOGICAL REACTIONS | NANOSYSTEMS L.L.C. (US) | 1997-04-03 | — | — | WO | disclosed |
| US-5587143-A | ADSORBED ON SURFACE | NANOSYSTEMS L.L.C. (US) | 1996-12-24 | — | — | US | disclosed |
| US-5569448-A | FOR PARTICLES CONTAINING THERAPEUTIC OR DIAGNOSTIC AGENTS; AUTOCLAVE STABILITY | NANO SYSTEMS L.L.C. (US) | 1996-10-29 | — | — | US | disclosed |
| US-5565188-A | Polyalkylene block copolymers as surface modifiers for nanoparticles | NANOSYSTEMS L.L.C. (US) | 1996-10-15 | — | — | US | disclosed |
| WO-1996025918-A1 | AEROSOLS CONTAINING NANOPARTICLE DISPERSIONS | NANOSYSTEMS L.L.C. (US) | 1996-08-29 | — | — | WO | disclosed |
| WO-1996025921-A1 | POLYALKYLENE BLOCK COPOLYMERS AS SURFACE MODIFIERS FOR NANOPARTICLES | NANOSYSTEMS L.L.C. (US) | 1996-08-29 | — | — | WO | disclosed |
| WO-1996000567-A1 | BUTYLENE OXIDE-ETHYLENE OXIDE BLOCK COPOLYMER SURFACTANTS AS STABILIZER COATINGS FOR NANOCRYSTAL FORMULATION | NANOSYSTEMS L.L.C. (US) | 1996-01-11 | — | — | WO | disclosed |
| US-5340564-A | Heat sterilized nanoparticles with adsorbed surface modifier | STERLING WINTHROP INC. (US) | 1994-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210251900-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY | SGMS1, CETP, APOB | LMNA 615/4885SMN1; SMN2 1151/4885ALDH1A1 1989/4885 |
| US-10952965-B2 | Compositions and methods for drug delivery | SGMS1, CETP, APOB | LMNA 615/4885SMN1; SMN2 1151/4885ALDH1A1 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.